DrugPatentWatch Database Preview

Drugs in Development Information for Ganitumab

« Back to Dashboard

Summary for Ganitumab

US Patents	10
International Patents	194
US Patent Applications	0
WIPO Patent Applications	0
Japanese Patent Applications	0
Clinical Trial Progress	Phase 2 (2014-12-01)
Vendors	0

US Patents for Ganitumab

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Ganitumab		Multispecific constructs	AbbVie Stemcentrx LLC (North Chicago, IL)
Ganitumab		Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein	CureVac AG (Tubingen, DE)
Ganitumab		P97 fragments with transfer activity	biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)
Ganitumab		Meditopes and meditope-binding antibodies and uses thereof	City of Hope (Duarte, CA)
Ganitumab		Fragments of p97 and uses thereof	biOasis Technologies, Inc. (Richmond, CA)
Ganitumab		Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein	CureVac AG (Tubingen, DE)

International Patents for Ganitumab

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Ganitumab	Canada	2900764	2033-02-08
Ganitumab	European Patent Office	2954056	2033-02-08
Ganitumab	Hong Kong	1218930	2033-02-08
Ganitumab	Japan	2016509014	2033-02-08
Ganitumab	World Intellectual Property Organization (WIPO)	2014124326	2033-02-08
Ganitumab	Australia	2013220749	2032-02-15